300347 Stock Overview
Provides contract research organization services in the People’s Republic of China and internationally.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 2/6 |
Past Performance | 2/6 |
Financial Health | 6/6 |
Dividends | 5/6 |
Rewards
Risk Analysis
No risks detected for 300347 from our risk checks.
Hangzhou Tigermed Consulting Co., Ltd Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥50.92 |
52 Week High | CN¥73.19 |
52 Week Low | CN¥36.12 |
Beta | 0.66 |
11 Month Change | 2.62% |
3 Month Change | -11.75% |
1 Year Change | -24.54% |
33 Year Change | -67.69% |
5 Year Change | 1.39% |
Change since IPO | 1,122.08% |
Recent News & Updates
Hangzhou Tigermed Consulting (SZSE:300347) Is Increasing Its Dividend To CN¥0.568
Jul 12Is Hangzhou Tigermed Consulting (SZSE:300347) A Risky Investment?
Jun 26An Intrinsic Calculation For Hangzhou Tigermed Consulting Co., Ltd (SZSE:300347) Suggests It's 35% Undervalued
Jun 07Recent updates
Hangzhou Tigermed Consulting (SZSE:300347) Is Increasing Its Dividend To CN¥0.568
Jul 12Is Hangzhou Tigermed Consulting (SZSE:300347) A Risky Investment?
Jun 26An Intrinsic Calculation For Hangzhou Tigermed Consulting Co., Ltd (SZSE:300347) Suggests It's 35% Undervalued
Jun 07Hangzhou Tigermed Consulting Co., Ltd Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Apr 28Hangzhou Tigermed Consulting Co., Ltd (SZSE:300347) Stock Catapults 27% Though Its Price And Business Still Lag The Market
Apr 08Hangzhou Tigermed Consulting's (SZSE:300347) Profits Appear To Have Quality Issues
Apr 04Hangzhou Tigermed Consulting Co., Ltd Just Missed Earnings - But Analysts Have Updated Their Models
Apr 01Shareholder Returns
300347 | CN Life Sciences | CN Market | |
---|---|---|---|
7D | -2.2% | -1.4% | -2.8% |
1Y | -24.5% | -39.5% | -21.0% |
Return vs Industry: 300347 exceeded the CN Life Sciences industry which returned -39.2% over the past year.
Return vs Market: 300347 underperformed the CN Market which returned -20.6% over the past year.
Price Volatility
300347 volatility | |
---|---|
300347 Average Weekly Movement | 5.7% |
Life Sciences Industry Average Movement | 6.0% |
Market Average Movement | 5.8% |
10% most volatile stocks in CN Market | 9.0% |
10% least volatile stocks in CN Market | 3.9% |
Stable Share Price: 300347 has not had significant price volatility in the past 3 months.
Volatility Over Time: 300347's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2004 | 9,701 | Xiaochun Cao | www.tigermedgrp.com |
Hangzhou Tigermed Consulting Co., Ltd provides contract research organization services in the People’s Republic of China and internationally. It operates in Clinical Trial Solutions, and Clinical-related and Laboratory Services segments. The company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monitoring, regulatory affairs, data management and statistical analysis, clinical development strategy, site management, subject recruitment, medical device/ in vitro diagnostics, multi-region clinical trial, and vaccine clinical trial services.
Hangzhou Tigermed Consulting Co., Ltd Fundamentals Summary
300347 fundamental statistics | |
---|---|
Market cap | CN¥40.80b |
Earnings (TTM) | CN¥1.69b |
Revenue (TTM) | CN¥7.24b |
25.9x
P/E Ratio6.1x
P/S RatioIs 300347 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
300347 income statement (TTM) | |
---|---|
Revenue | CN¥7.24b |
Cost of Revenue | CN¥4.48b |
Gross Profit | CN¥2.76b |
Other Expenses | CN¥1.07b |
Earnings | CN¥1.69b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 29, 2024
Earnings per share (EPS) | 1.96 |
Gross Margin | 38.10% |
Net Profit Margin | 23.36% |
Debt/Equity Ratio | 13.2% |
How did 300347 perform over the long term?
See historical performance and comparison